Hatabu Toshimitsu, Takada Tsuyoshi, Taguchi Nao, Suzuki Mamoru, Sato Kumiko, Kano Shigeyuki
Gunma University School of Health Sciences, 3-39-15 Showa-machi, Maebashi 371-8514, Japan.
Antimicrob Agents Chemother. 2005 Feb;49(2):493-6. doi: 10.1128/AAC.49.2.493-496.2005.
The emergence and spread of drug-resistant Plasmodium falciparum continue to pose problems in malaria chemotherapy. Therefore, it is necessary to identify new antimalarial drugs and therapeutic strategies. In the present study, the activity of a heat-treated form of amphotericin B (HT-AMB) against P. falciparum was evaluated. The efficacy and toxicity of HT-AMB were also compared with those of the standard formulation (AMB). HT-AMB showed significant activity against a chloroquine-resistant strain (strain K-1) and a chloroquine-susceptible strain (strain FCR-3) in vitro. The 50% inhibitory concentrations of HT-AMB were 0.32 +/- 0.03 mug/ml for strain K-1 and 0.33 +/- 0.03 mug/ml for strain FCR-3. In the presence of 1.0 mug of HT-AMB per ml, only pyknotic parasites were observed after 24 h of incubation of early trophozoites (ring forms). However, when late trophozoites and schizonts were cultured with 1.0 mug of HT-AMB per ml, those forms multiplied to ring forms but the number of infected erythrocytes did not increase. These results indicate that HT-AMB possesses potent antiplasmodial activity and that the drug is more effective against the ring-form stage than against the late trophozoite and schizont stages. HT-AMB was observed to have little cytotoxic effect against a human liver cell line (Chang liver cells). In conclusion, the results suggest that HT-AMB has promising properties and merits further in vivo investigations as a treatment for falciparum malaria.
耐氯喹恶性疟原虫的出现和传播持续给疟疾化疗带来问题。因此,有必要鉴定新的抗疟药物和治疗策略。在本研究中,评估了经热处理的两性霉素B(HT-AMB)对恶性疟原虫的活性。还将HT-AMB的疗效和毒性与标准制剂(AMB)进行了比较。HT-AMB在体外对氯喹耐药株(K-1株)和氯喹敏感株(FCR-3株)显示出显著活性。HT-AMB对K-1株的50%抑制浓度为0.32±0.03μg/ml,对FCR-3株为0.33±0.03μg/ml。在每毫升含1.0μg HT-AMB的情况下,早期滋养体(环状体)孵育24小时后仅观察到固缩的寄生虫。然而,当晚期滋养体和裂殖体与每毫升1.0μg HT-AMB一起培养时,这些形态增殖为环状体,但感染红细胞的数量没有增加。这些结果表明HT-AMB具有强大的抗疟原虫活性,且该药物对环状体阶段比对晚期滋养体和裂殖体阶段更有效。观察到HT-AMB对人肝癌细胞系(Chang肝癌细胞)几乎没有细胞毒性作用。总之,结果表明HT-AMB具有良好的特性,作为恶性疟的一种治疗方法值得进一步进行体内研究。